<DOC>
	<DOCNO>NCT02858999</DOCNO>
	<brief_summary>Plasma cell leukaemia rare variety multiple myeloma poor prognosis . Plasma cell leukaemia define : least 2,000 circulate plasma cell per µL blood leukocyte count high 10,000/µL 20 % plasma cell leukocyte count less 10,000/µL . Plasma cell leukaemia either primary , constitutes first manifestation disease , secondary set relapsed/refractory multiple myeloma . Primary plasma cell leukaemia ( PPL ) rare disease , represent 1 2 % case multiple myelomas diagnosis . As annual incidence multiple myeloma France 4,000 new case , estimate 40 80 new case PPL would observe year . Few data currently available literature concern pathophysiology therapeutic management PPL , derive retrospective series base small number patient . The prognosis PPL response conventional chemotherapy remain poor median survival 7 14 month . However , long survival obtain intensive therapy haematopoietic stem cell transplantation ( allogeneic autologous HSCT ) . The investigator propose perform prospective study management patient PPL age 70 year , combination laboratory study : 12 week induction chemotherapy liposomal Bortezomib-Dexamethasone-Doxorubicin ( PAD ) alternate Bortezomib-Dexamethasone-Cyclophosphamide ( VCD ) total 4 cycle . Peripheral blood stem cell collection mobilization G-CSF perform high-dose Cyclophosphamide chemotherapy . Autologous HSCT condition high-dose Melphalan perform follow month respond patient . During 3 month first autologous HSCT , allogeneic HSCT attenuate condition propose patient age 66 year complete remission suitable donor , another systematic autologous HSCT propose patient . For patient treat allogeneic HSCT , consolidation/maintenance therapy perform 3 month second autologous HSCT : 4 quarterly consolidation Bortezomib-Lenalidomide-Dexamethasone ( VRD ) maintenance 2 month Lenalidomide cycle , total duration one year . The laboratory assessment consist blood bone marrow sample systematically obtain diagnosis plasma cell phenotyping cytometry , cytogenetics , FISH , study gene expression profile SNParray . A DNA bank plasma bank constitute . The investigator also propose study residual disease cytometry ( first autologous HSCT , end consolidation/maintenance phase ) , increasingly appear major impact survival multiple myeloma .</brief_summary>
	<brief_title>Treatment Primary Plasma Cell Leukaemia Subjects Under Age 70</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<criteria>Patient primary plasma cell leukaemia correspond International Myeloma Working Group definition . Patient previously treat apart short course corticosteroid therapy ( dexamethasone 40 mg/day 4 day ) . Age ≥ 18 year &lt; 70 year . Patient able provide sign informed consent . Effective contraception justify ( oral contraception/protected intercourse ) . Consent obtain . Patient judicial protection , permanent temporary guardianship . Previously treat multiple myeloma , secondary plasma cell leukaemia . ECOG performance status &gt; 2 . History severe psychiatric illness , severe renal failure attributable PPL , heart failure ( ejection fraction &lt; 40 % ) , bilirubin &gt; 3N , transaminase gamma GT &gt; 4N . Peripheral neuropathy &gt; NCI grade 2 . Contraindication highdose corticosteroid , cyclophosphamide anthracyclines . Hypersensitivity bortezomib lenalidomide . Pregnant woman nurse mother . Malignant disease except basal cell carcinoma cervical carcinoma situ . Positive HIV serology ; active hepatitis B C. Participation clinical trial 60 day prior inclusion . Patient cover French national health insurance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>primary plasma cell leukaemia</keyword>
	<keyword>treatment</keyword>
</DOC>